KEI filed comments on the NIST Draft Green paper on the return from investment on federally funded R&D (See: https://www.keionline.org/29518). We expect the comment period to be extended, but filed this on January 9, 2018, as an initial submission. KEI-comments-NIST-SP-1234-ROI-9Jan2018… Continue Reading →
In December 2018, the Department of Commerce National Institute of Standards (NIST) published NIST Special Publication 1234, “Return on Investment Initiative for Unleashing American Innovation” as a draft Green Paper. According to the initial release, before the government shutdown, comments… Continue Reading →
Below are the comments filed by Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) regarding a prospective grant of an exclusive license of NIH-owned patents to the California-based company Midissia Therapeutics. The prospective exclusive license is… Continue Reading →
Attached are comments from 8 health and fair groups regarding a prospective grant of an exclusive license to NIH owned patent, for the development of an Anti-Mesothelin Chimeric Antigen Receptor (CAR) for the treatment of human Cancer, to Atara Biotherapeutics… Continue Reading →
July 10, 2018 Sury Vepa, Ph.D., J.D., Senior Licensing and Patenting Manager National Center for Advancing Translational Sciences National Institutes of Health Email sury.vepa@nih.gov Re: Prospective Grant of Exclusive Patent License: Mutant IDH1 Inhibitors Useful for Treating Cancer to Apexx… Continue Reading →
UPDATE: On July 13, 2018, KEI received a response to our comments on the prospective license to be given to ERYTHRYx Therapeutics. The brief response simply stated that NIH had already assessed the company to meet their technical and financial… Continue Reading →
Below at comments sent by KEI, UACT and HealthGap, regarding a proposed exclusive license to Morphiex Biotherapeutics, an entity for which little is known. The license concerns “Use of the CD47 Phosphorodiamidate Morpholino Oligomers for the Treatment, Prevention, and Diagnosis… Continue Reading →
FOR IMMEDIATE RELEASE April 5, 2018 kim.treanor@keionline.org (202)-332-2670 Six organizations are asking Department of Health and Human Services Secretary Alex Azar to take actions to lower the price of eteplirsen, a drug sold under the brand name Exondys 51, to… Continue Reading →
On March 21, 2018, KEI asked the NIH to investigate the failure of James Griffin, the Dana-Farber Cancer Institute and Novartis to disclose millions of dollars in NIH grants related to two patents for the leukemia drug midostaurin, marketed by… Continue Reading →
Bayh-Dole cases involving royalty free or march-in rights 1997 Cellpro case This was a strong case involving two competing medical devices, both invented on NIH grants, and a bad ending. The NIH rejection of the Cellpro march-in request led to… Continue Reading →